Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae
Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae
复制标题
DOI：
10.1128/aac.01420-10
复制
发表时间：
2011-06-01
影响因子：
4.9
通讯作者：
Nicolau, David P.
中科院分区：
文献类型：
--
作者：
Bulik, Catharine C.;Nicolau, David P.
产生碳青霉烯酶的肺炎克雷伯菌 (KPC) 的治疗选择有限，使其成为一种可怕的病原体。之前我们已经证明药效优化的多尼培南对 KPC 的活性增强。利用 KPC 对厄他培南增加的亲和力，我们评估了厄他培南和多尼培南组合在体外恒化器和体内小鼠大腿感染模型中的功效。总体而言，多尼培南加厄他培南的组合比单独使用任一药物的疗效增强。
The limited treatment options available for carbapenemase-producing Klebsiella pneumoniae (KPC) have made it a formidable pathogen. Previously we have shown the enhanced activity of pharmacodynamically optimized doripenem against KPC. Capitalizing on KPC's increased affinity for ertapenem, we evaluated the efficacy of a combination of ertapenem and doripenem in both an in vitro chemostat and an in vivo murine thigh infection model. Overall, the combination of doripenem plus ertapenem demonstrated enhanced efficacy over either agent alone.